Reduced-Fluence Photodynamic Therapy

Uses

Risks & contraindications

Comparisons

Evidence quality

Other

Highlighted claims

• PDT remains unapproved for CSC in every country and is used off-label worldwide. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
• REPLAY was preceded by no large prospective placebo-controlled randomised trial specifically evaluating rf-PDT for chronic CSC. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
• Photodynamic therapy is globally recognised as the first-line treatment for chronic CSC. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
• In Japan, off-label CSC treatments are not covered by national health insurance. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
• Reduced-fluence PDT became the preferred clinical approach for CSC. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
• Reduced-intensity PDT protocols achieved comparable efficacy with fewer complications than full-fluence PDT. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial